SLC6A19: A Protein Involved in Neurotransmitter Transport and Psychiatric Disorders

Target Name: SLC6A19

NCBI ID: G340024

SLC6A19

Other Name(s): solute carrier family 6 (neurotransmitter transporter), member 19 | system B(0) neutral amino acid transporter AT1 | solute carrier family 6 (neutral amino acid transporter), member 19 | solute carrier family 6 member 19 | Sodium-dependent amino acid transporter | sodium-dependent amino acid transporter system B0 | B0AT1 | System B(0) neutral amino acid transporter AT1 | Amino acid transporter system B0 | Solute carrier family 6 (neurotransmitter transporter), member 19 | Sodium-dependent neutral amino acid transporter B(0)AT1 | S6A19_HUMAN | HND | Solute carrier family 6 (neutral amino acid transporter), member 19 | System B0 neutral amino acid transporter | broad neutral amino acid transporter 1 | Solute carrier family 6 member 19 | system B0 neutral amino acid transporter

SLC6A19: A Protein Involved in Neurotransmitter Transport and Psychiatric Disorders

SLC6A19 is a protein that belongs to the SLC6A family, which is a well-known transmembrane protein family that is involved in various physiological processes in the body. SLC6A19 is a member of the SLC6A family, and its function is still not well understood. However, research has shown that it is involved in the transport of various substances in the brain, including neurotransmitters such as dopamine, serotonin, and endocannabinoids.

SLC6A19 is a transmembrane protein that is located on the outer membrane of cells. It consists of a single transmembrane domain and a cytoplasmic tail that is involved in protein-protein interactions. The cytoplasmic tail of SLC6A19 is composed of a unique domain that is known as the N-terminal cytoplasmic tail. This domain is involved in protein-protein interactions and has been shown to play a role in the regulation of various cellular processes.

SLC6A19 is expressed in various tissues and cells of the body, including the brain. It is highly expressed in the prefrontal cortex, which is the part of the brain that is responsible for various higher-order cognitive functions. SLC6A19 is also expressed in other tissues, including the pancreas, gut, and heart.

SLC6A19 is involved in the transport of various neurotransmitters in the brain. One of its main functions is the transport of dopamine, which is a neurotransmitter that plays a role in motor coordination, mood regulation, and other cognitive processes. SLC6A19 is known to be involved in the regulation of dopamine levels in the brain, and research has shown that it is a critical transport protein for dopamine.

SLC6A19 is also involved in the transport of serotonin, which is another neurotransmitter that is involved in mood regulation and other cognitive processes. Serotonin is known to play a role in regulating mood, appetite, and sleep, and SLC6A19 is involved in the regulation of serotonin levels in the brain.

SLC6A19 is also involved in the transport of endocannabinoids, which are compounds that are derived from the cannabis plant. Endocannabinoids are involved in various physiological processes in the body, including pain relief, inflammation, and neurotransmission. SLC6A19 is known to be involved in the regulation of endocannabinoid levels in the brain, and research has shown that it is a critical transport protein for endocannabinoids.

SLC6A19 is a potential drug target or biomarker for various psychiatric and neurological disorders. Research has shown that SLC6A19 is involved in the regulation of various psychiatric disorders, including depression, anxiety, and schizophrenia. It is also involved in the regulation of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

SLC6A19 is also a potential biomarker for various psychiatric and neurological disorders. Studies have shown that SLC6A19 is involved in the regulation of various psychiatric symptoms, including depression, anxiety, and psychosis. It is also involved in the regulation of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

In conclusion, SLC6A19 is a transmembrane protein that is involved in various physiological processes in the body, including the transport of neurotransmitters such as dopamine, serotonin, and endocannabinoids. It is a potential drug target or biomarker for various psychiatric and neurological disorders. Further research is needed to fully understand the functions of SLC6A19 and its potential as a drug.

Protein Name: Solute Carrier Family 6 Member 19

Functions: Transporter that mediates resorption of neutral amino acids across the apical membrane of renal and intestinal epithelial cells (PubMed:15286787, PubMed:15286788, PubMed:18424768, PubMed:18484095, PubMed:19185582, PubMed:26240152). This uptake is sodium-dependent and chloride-independent (PubMed:15286787, PubMed:19185582, PubMed:15286788). Requires CLTRN in kidney or ACE2 in intestine for cell surface expression and amino acid transporter activity (PubMed:19185582, PubMed:18424768)

The "SLC6A19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets